Immunocore and GSK pick third cancer immunotherapy target

07:46 EDT 4 Jul 2017 | pharmaphorum

Immunocore, one of UK biotech's brightest hopes, has selected a third target as part of its immuno-oncology partnership with GlaxoSmithKline. The collaboration was first launched in 2013, and is based around Immunocore’s T Cell Receptor (TCR) pl...

Original Article: Immunocore and GSK pick third cancer immunotherapy target


More From BioPortfolio on "Immunocore and GSK pick third cancer immunotherapy target"

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...